Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Rocket Pharmaceuticals, Inc.    RCKT

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsReco analystes

Rocket Pharmaceuticals : Announces Participation at Upcoming Conferences

11/24/2020 | 07:04am EST

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the following upcoming conferences:

  • Piper Sandler 32nd Annual Virtual Healthcare Conference
    • Tuesday, December 1, 2020
  • Evercore ISI 3rd Annual HealthCONx Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to participate in a fireside chat on Wednesday, December 2, 2020, at 3:30 p.m. Eastern Time.

A live audio webcast of the presentation will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conferences.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.


© Business Wire 2020
All news about ROCKET PHARMACEUTICALS, INC.
01/11ROCKET PHARMACEUTICALS : Announces Buildout of R&D and Manufacturing Facility to..
BU
01/07ROCKET PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8..
AQ
01/06ROCKET PHARMACEUTICALS : Announces Participation at the 39th Annual J.P. Morgan ..
BU
2020INSIDER TRENDS : Rocket Pharmaceuticals Insider Disposition Eases Back 90-Days o..
MT
2020ROCKET PHARMACEUTICALS : UBS Starts Rocket Pharmaceuticals at Buy With $75 Price..
MT
2020ROCKET PHARMACEUTICALS : Significant Insider Buying Reverses neutral Trend over ..
MT
2020ROCKET PHARMACEUTICALS : Announces Closing of Public Offering and Full Exercise ..
AQ
2020INSIDER TRENDS : 90-Day Insider Selling Trend at Rocket Pharmaceuticals Slowed w..
MT
2020ROCKET PHARMACEUTICALS : Announces Closing of Public Offering and Full Exercise ..
BU
2020ROCKET PHARMACEUTICALS : Other Events (form 8-K/A)
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -109 M - -
Net cash 2020 215 M - -
P/E ratio 2020 -27,1x
Yield 2020 -
Capitalization 3 139 M 3 139 M -
EV / Sales 2020 -
EV / Sales 2021 272x
Nbr of Employees 84
Free-Float 91,8%
Chart ROCKET PHARMACEUTICALS, INC.
Duration : Period :
Rocket Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 70,50 $
Last Close Price 52,42 $
Spread / Highest target 90,8%
Spread / Average Target 34,5%
Spread / Lowest Target 6,83%
EPS Revisions
Managers and Directors
NameTitle
Gaurav Shah President, Chief Executive Officer & Director
Roderick T. Wong Chairman
Kinnari Patel Chief Operating Officer & EVP-Development
Carlos Garcia-Parada Chief Financial Officer
Jonathan David Schwartz Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ROCKET PHARMACEUTICALS, INC.-4.41%3 139
GILEAD SCIENCES, INC.14.97%83 961
VERTEX PHARMACEUTICALS0.97%62 055
WUXI APPTEC CO., LTD.18.76%60 054
REGENERON PHARMACEUTICALS10.84%56 517
BEIGENE, LTD.38.16%32 552